Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial - 01/07/14
, Pascale Cervera, MD b, Stéphanie Foulon, MSc a, Tanja Trarbach, MD c, Christelle de la Fouchardière, MD d, Eveline Boucher, MD e, Laetitia Fartoux, MD b, Sandrine Faivre, ProfMD f, Jean-Frédéric Blanc, ProfMD g, Frédéric Viret, MD h, Eric Assenat, MD i, Thomas Seufferlein, ProfMD j, Thomas Herrmann, ProfMD k, Julien Grenier, MD l, Pascal Hammel, ProfMD f, Matthias Dollinger, MD m, Thierry André, ProfMD n, Philipp Hahn, MD o, Volker Heinemann, ProfMD p, Vanessa Rousseau, PhD a, Michel Ducreux, ProfMD a, Jean-Pierre Pignon, MD a, Dominique Wendum, ProfMD b, Olivier Rosmorduc, ProfMD b, Tim F Greten, ProfMD qon behalf of the BINGO investigators†
Summary |
Background |
Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated the addition of cetuximab to chemotherapy in patients with advanced biliary cancers.
Methods |
In this non-comparative, open-label, randomised phase 2 trial, we recruited patients with locally advanced (non-resectable) or metastatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma and a WHO performance status of 0 or 1 from 18 hospitals across France and Germany. Eligible patients were randomly assigned (1:1) centrally with a minimisation procedure to first-line treatment with gemcitabine (1000 mg/m2) and oxaliplatin (100 mg/m2) with or without cetuximab (500 mg/m2), repeated every 2 weeks until disease progression or unacceptable toxicity. Randomisation was stratified by centre, primary site of disease, disease stage, and previous treatment with curative intent or adjuvant therapy. Investigators who assessed treatment response were not masked to group assignment. The primary endpoint was the proportion of patients who were progression-free at 4 months, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00552149.
Findings |
Between Oct 10, 2007, and Dec 18, 2009, 76 patients were assigned to chemotherapy plus cetuximab and 74 to chemotherapy alone. 48 (63%; 95% CI 52–74) patients assigned to chemotherapy plus cetuximab and 40 (54%; 43–65) assigned to chemotherapy alone were progression-free at 4 months. Median progression-free survival was 6·1 months (95% CI 5·1–7·6) in the chemotherapy plus cetuximab group and 5·5 months (3·7–6·6) in the chemotherapy alone group. Median overall survival was 11·0 months (9·1–13·7) in the chemotherapy plus cetuximab group and 12·4 months (8·6–16·0) in the chemotherapy alone group. The most common grade 3–4 adverse events were peripheral neuropathy (in 18 [24%] of 76 patients who received chemotherapy plus cetuximab vs ten [15%] of 68 who received chemotherapy alone), neutropenia (17 [22%] vs 11 [16%]), and increased aminotransferase concentrations (17 [22%] vs ten [15%]). 70 serious adverse events were reported in 39 (51%) of 76 patients who received chemotherapy plus cetuximab (34 events in 19 [25%] patients were treatment-related), whereas 41 serious adverse events were reported in 25 (35%) of 71 patients who received chemotherapy alone (20 events in 12 [17%] patients were treatment-related). One patient died of atypical pneumonia related to treatment in the chemotherapy alone group.
Interpretation |
The addition of cetuximab to gemcitabine and oxaliplatin did not seem to enhance the activity of chemotherapy in patients with advanced biliary cancer, although it was well tolerated. Gemcitabine and platinum-based combination should remain the standard treatment option.
Funding |
Institut National du Cancer, Merck Serono.
Le texte complet de cet article est disponible en PDF.Plan
Vol 15 - N° 8
P. 819-828 - juillet 2014 Retour au numéro
Article précédent
- Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
- Ajay Vora, Nick Goulden, Chris Mitchell, Jeremy Hancock, Rachael Hough, Clare Rowntree, Anthony V Moorman, Rachel Wade
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- Gary Middleton, Paul Silcocks, Trevor Cox, Juan Valle, Jonathan Wadsley, David Propper, Fareeda Coxon, Paul Ross, Srinivasan Madhusudan, Tom Roques, David Cunningham, Stephen Falk, Nick Wadd, Mark Harrison, Pippa Corrie, Tim Iveson, Angus Robinson, Karen McAdam, Martin Eatock, Jeff Evans, Caroline Archer, Tamas Hickish, Angel Garcia-Alonso, Marianne Nicolson, William Steward, Alan Anthoney, William Greenhalf, Victoria Shaw, Eithne Costello, Dean Naisbitt, Charlotte Rawcliffe, Gemma Nanson, John Neoptolemos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?